OBJECTIVES: IDA/IDS is common in pregnancy, postpartum, inflammatory bowel disease, chronic kidney disease, chronic heart failure, menorrhagia/hypermenorrhagia, cancer and following surgery. We estimate the BI associated with substituting iron sucrose (standard) with ferric carboxymaltose (new treatment), which allows for the application of higher dosages in a shorter time. The analysis adopted the perspective of the Swiss mandatory health insurance (MHI) covering the above indications and is based on real-life data to verify the hypothetical BI estimated prior to launch. METHODS: Resource use (no. of patients, dosage per application, no. of applications) was based on recent primary data (Polyquest Prescriber Analysis, Anemia Patient Record Study in Switzerland). Personnel costs were estimated using the Swiss Tarmed fee-for-service reimbursement system. Drug costs and costs of materials used were based on official tariffs (Spezialitätenliste, MiGeL). Real-life IMS sales data of both products were used to verify the BI model. RESULTS: Ferric carboxymaltose was associated with cost savings of 30-44% compared to iron sucrose based on costs of CHF 101/ 210/ 420 and CHF 144/ 375/ 721 per 200/ 500/ 1000mg treatment cycle, respectively. This leads to cost savings of CHF 15-33 million per year to the Swiss MHI across all indications in the first 3 years post-launch, due to reductions in personnel costs. Ferric carboxymaltose was shown to be cost-saving in all indications except dialysis (due to flat-fee reimbursement).  Sensitivity analyses showed the amount of cost savings to be sensitive to changes in the number of inpatients (10-20% of total) treated with intravenous iron (due to flat-fee reimbursement). CONCLUSIONS: Treating IDA/IDS involves substantial costs to the Swiss MHI. Substitution of iron sucrose with ferric carboxymaltose may help to reduce these due to reduced personnel costs. This novel type of real-life BIA will be of increasing interest as conditional reimbursement increases.